Skip to main content

Table 2 Studies of mesothelin as a prognostic biomarker

From: A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

Reference n Males (%) Median age Receiving CT (%) ORR (%) OS (months) PFS (months)
Grigoriu et al. 2007 [13] 96 81 65 85 NR m > 3.5 = 7.0 NR
m ≤ 3.5 = 19.0
P = 0.003
Cristaudo et al. 2007 [34] 107 83.2 69 NR NR m > 1 = 9.8 NR
m ≤ 1 = 21.5
P < 0.001
Creaney et al. 2011 [25] 97 89 66 69   m < 1 = 20.3 NR
m > 5 = 12.5
p = 0.01
Mori et al. 2013 [35] 26 21 5 26 19.2 m < 0.469* = 26.6 NR
m > 0.469* = 10.3
p = 0.027
This study 53 68 69 57** m > 2.7 = 26 m > 2.7 = 11.3 m > 2.7 = 5.1
      m ≤ 2.7 = 0 m ≤ 2.7 = 17.2 m ≤ 2.7 = 8.0
        P = 0.059
       P = 0.088  
  1. n = number patients; ORR, overall response rate; OS, median overall survival; PFS, mean progression free survival; NR, not reported; CT, chemotherapy; m, mesothelin level in nmol/L.
  2. *This study used the median mesothelin index, calculated by Log2 (mesothelin level after 2 courses of chemotherapy level/mesothelin level prior to chemotherapy). Assay specifically detected N-terminal 31 kDa fragment.
  3. **18 patients (34%) had a pre-chemotherapy mesothelin level and are therefore included in the response analysis.
  4. If the PFS is analysed as a continuous variable for every unit increase the there is a HR of 1.03, p = 0.013.